A Prospective Randomised Comparison of CMF versus Sequential Epirubicin Followed by CMF as Adjuvant Chemotherapy for Women with Early Breast Cancer
| ISRCTN | ISRCTN35478997 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN35478997 |
| Protocol serial number | BR9601 |
| Sponsor | Pharmacia Ltd & Upjohn (UK) |
| Funder | Pharmacia and Upjohn (UK) |
- Submission date
- 19/08/2002
- Registration date
- 19/08/2002
- Last edited
- 08/10/2012
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Contact information
Dr - -
Scientific
Scientific
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Breast cancer |
| Intervention | 1. Group A: Chemotherapy, cyclophosphamide, methotrexate and 5-fluorouracil (CMF) repeated every 3 weeks for eight cycles 2. Group B: Chemotherapy, epirubicin repeated every 3 weeks for four cycles followed by CMF repeated every 3 weeks for four cycles |
| Intervention type | Other |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 30/04/2001 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Female |
| Key inclusion criteria | 1. Histologically confirmed breast cancer 2. Histologically confirmed axillary node metastases 3. Fit to receive chemotherapy on either arm of the trial 4. Adequate hepatic, renal and bone marrow function 5. No previous chemotherapy 6. No prior or concomitant malignancy, except basal cell carcinoma or in situ carcinoma of the cervix 7. No bilateral breast tumours or locally advanced or metastatic breast cancer, including supraclavicular fossa metastases |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/01/2000 |
| Date of final enrolment | 30/04/2001 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 02/11/2006 | Yes | No |